Pharmaceutical Following a review of the risk of meningioma (a rare tumor of the membranes covering the brain and spinal cord) in patients taking cyproterone, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended that medicines containing 10mg or more of cyproterone should only be used for hirsutism (excessive hair growth), androgenic alopecia (hair loss), acne and seborrhoea (excessively oily skin) once other treatment options, including treatment with lower doses, have failed. 14 February 2020